This article presents the first update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis (AS) based on a systematic review of existing literature, expert discussions, and input from patients and physiotherapists. The update includes four overarching principles and 11 bullet points, with a mean strength of recommendation score of 9.1 (range 8-10). The recommendations cover all age groups fulfilling the modified New York criteria for AS, regardless of extra-articular manifestations, and address both pharmacological and non-pharmacological interventions. Key points include the importance of multidisciplinary treatment, maximizing long-term health-related quality of life, and the need for shared decision-making between patients and rheumatologists. The update also highlights the differential effects of anti-TNF therapy on musculoskeletal manifestations and extra-articular manifestations, and introduces a new recommendation for switching anti-TNF agents in patients who do not respond to initial treatment.This article presents the first update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis (AS) based on a systematic review of existing literature, expert discussions, and input from patients and physiotherapists. The update includes four overarching principles and 11 bullet points, with a mean strength of recommendation score of 9.1 (range 8-10). The recommendations cover all age groups fulfilling the modified New York criteria for AS, regardless of extra-articular manifestations, and address both pharmacological and non-pharmacological interventions. Key points include the importance of multidisciplinary treatment, maximizing long-term health-related quality of life, and the need for shared decision-making between patients and rheumatologists. The update also highlights the differential effects of anti-TNF therapy on musculoskeletal manifestations and extra-articular manifestations, and introduces a new recommendation for switching anti-TNF agents in patients who do not respond to initial treatment.